Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal



Page Path
HOME > Search
1 "Canagliflozin"
Article category
Publication year
A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
Chang Hee Jung, Jung Eun Jang, Joong-Yeol Park
Diabetes Metab J. 2014;38(4):261-273.   Published online August 20, 2014
  • 7,679 View
  • 135 Download
  • 63 Web of Science
  • 59 Crossref
AbstractAbstract PDFPubReader   

Type 2 diabetes mellitus (T2DM) is a complex endocrine and metabolic disorder, and a major public health problem that is rapidly increasing in prevalence. Although a wide range of pharmacotherapies for glycemic control is now available, management of T2DM remains complex and challenging. The kidneys contribute immensely to glucose homeostasis by reabsorbing glucose from the glomerular filtrate. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a new class of antidiabetic agents that inhibit glucose absorption from the kidney independent of insulin, offer a unique opportunity to improve the outcomes of patients with T2DM. In this review, we provide an overview of two globally-approved SGLT2 inhibitors, dapagliflozin and canagliflozin, and discuss their effects and safety. This information will help clinicians to decide whether these drugs will benefit their patients.


Citations to this article as recorded by  
  • Quantitative analysis of low-content impurity crystal forms in canagliflozin tablets by NIR solid-state analysis technique
    Mingdi Liu, Jichao Liu, Qiuhong Wang, Ping Song, Haichao Li, Zan Sun, Chenglong Shi, Weibing Dong
    Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy.2024; 311: 124000.     CrossRef
  • A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin
    Pablo Lapuerta, Silvia Urbina, Jiaojuan He, Alyssa Wittle, Chenghai Li, Tong Li, Helen Wang, Marcus Hompesch
    Clinical Pharmacology & Therapeutics.2024; 115(6): 1383.     CrossRef
  • Ketoacidosis and SGLT2 Inhibitors: A Narrative Review
    Carmela Morace, Giuseppe Lorello, Federica Bellone, Cristina Quartarone, Domenica Ruggeri, Annalisa Giandalia, Giuseppe Mandraffino, Letteria Minutoli, Giovanni Squadrito, Giuseppina T. Russo, Herbert Ryan Marini
    Metabolites.2024; 14(5): 264.     CrossRef
  • Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial
    Kazuki Shiina, Hirofumi Tomiyama, Atsushi Tanaka, Takumi Imai, Itaru Hisauchi, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Kaoru Dohi, Haruo Kamiya, Keisuke Kida, Toshihisa Anzai, Taishiro Chikamori, Koichi Node, Masayoshi Ajioka, Junya Ako, Rie Amano, Mit
    Hypertension Research.2023; 46(2): 495.     CrossRef
  • Ecofriendly appraisal of stability‐indicating high‐performance chromatographic assay of canagliflozin and metformin with their toxic impurities; in silico toxicity prediction
    Raghda A. Emam, Aml A. Emam
    Journal of Separation Science.2023;[Epub]     CrossRef
  • Effect of sodium‐glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta‐analysis
    Yanbei Duo, Junxiang Gao, Tao Yuan, Weigang Zhao
    Journal of Diabetes.2023; 15(1): 58.     CrossRef
  • Quantitative analysis of low content polymorphic impurities in canagliflozin tablets by PXRD, NIR, ATR-FITR and Raman solid-state analysis techniques combined with stoichiometry
    Mingdi Liu, Jichao Liu, Qiuhong Wang, Ping Song, Haichao Li, Songgu Wu, Junbo Gong
    Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy.2023; 293: 122458.     CrossRef
  • SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
    Bartosz Rolek, Mateusz Haber, Magdalena Gajewska, Sylwester Rogula, Arkadiusz Pietrasik, Aleksandra Gąsecka
    Journal of Cardiovascular Development and Disease.2023; 10(8): 322.     CrossRef
  • Cardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes
    Somayeh Nazari, Hossein Mirkhani
    Current Diabetes Reviews.2023;[Epub]     CrossRef
  • Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study
    Jaehyuk Jang, Soyoon Park, Soohyun Kim, Sung-Hwan Kim, Yong-Seog Oh, Young Kyoung Sa, Youmi Hwang, Sung-Won Jang, Sang-Hyun Ihm, Young Choi
    European Journal of Preventive Cardiology.2023;[Epub]     CrossRef
  • Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extensio
    Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, Kun-Ho Yoon
    Diabetes & Metabolism Journal.2023; 47(6): 808.     CrossRef
  • Novel perspective on cardiovascular adverse event profiles due to treatment with sodium-glucose transport protein 2 (SGLT2) inhibitors in the Japanese Adverse Drug Event Report (JADER) database
    Koji Suematsu
    Personalized Medicine Universe.2023; 12: 23.     CrossRef
  • The fate of flavonoids after oral administration: a comprehensive overview of its bioavailability
    Abid Naeem, Yang Ming, Hu Pengyi, Kang Yong Jie, Liu Yali, Zhang Haiyan, Xiao Shuai, Li Wenjing, Wu Ling, Zhang Ming Xia, Liu Shan Shan, Zheng Qin
    Critical Reviews in Food Science and Nutrition.2022; 62(22): 6169.     CrossRef
  • Add-on therapy with dapagliflozin in routine outpatient care of type 2 diabetes patients from Turkey: a retrospective cohort study on HbA1c, body weight, and blood pressure outcomes
    Derun Taner Ertugrul, Erdal Kan, Cigdem Bahadir Tura, Haci Bayram Tugtekin, Hayati Ayakta, Mehmet Celebioglu, Ceren Yılmaz, Onur Utebay, Ilhan Yetkin, Eren Gurkan, Kerem Sezer, Ramazan Gen, Suleyman Ozcaylak, Yildiz Okuturlar, Mehmet Coskun, Nilgun Govec
    International Journal of Diabetes in Developing Countries.2022; 42(1): 147.     CrossRef
  • Sodium–glucose cotransporter 2 inhibitors do not increase the risk of fractures in real‐world clinical practice in Korea: A national observational cohort study
    Kyoung Hwa Ha, Dae Jung Kim, Yong Jun Choi
    Journal of Diabetes Investigation.2022; 13(6): 986.     CrossRef
  • Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function
    Yuki Yamauchi, Akinobu Nakamura, Takashi Yokota, Kiyohiko Takahashi, Shinichiro Kawata, Kazuhisa Tsuchida, Kazuno Omori, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Toshihisa Anzai, Shinya Tanaka, Yasuo Terauchi, Hideaki Miyoshi, Tatsuya Atsumi
    Scientific Reports.2022;[Epub]     CrossRef
  • Blood glucose levels and bodyweight change after dapagliflozin administration
    Hyunah Kim, Seung‐Hwan Lee, Hyunyong Lee, Hyeon Woo Yim, Jae‐Hyoung Cho, Kun‐Ho Yoon, Hun‐Sung Kim
    Journal of Diabetes Investigation.2021; 12(9): 1594.     CrossRef
  • Dapagliflozin Improves Cardiac Hemodynamics and Mitigates Arrhythmogenesis in Mitral Regurgitation‐Induced Myocardial Dysfunction
    Yu‐Wen Lin, Chin‐Yu Chen, Jhih‐Yuan Shih, Bor‐Chih Cheng, Ching‐Ping Chang, Mao‐Tsun Lin, Chung‐Han Ho, Zhih‐Cherng Chen, Sudeshna Fisch, Wei‐Ting Chang
    Journal of the American Heart Association.2021;[Epub]     CrossRef
  • Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
    Ja Young Jeon, Kyoung Hwa Ha, Dae Jung Kim
    Diabetes & Metabolism Journal.2021; 45(4): 505.     CrossRef
  • Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway
    Ji-Yeon Lee, Minyoung Lee, Ji Young Lee, Jaehyun Bae, Eugene Shin, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
    Diabetes & Metabolism Journal.2021; 45(6): 921.     CrossRef
  • SGLT2i: beyond the glucose-lowering effect
    Lihua Ni, Cheng Yuan, Guopeng Chen, Changjiang Zhang, Xiaoyan Wu
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
    Eugene Han, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
    Journal of Clinical Medicine.2020; 9(1): 259.     CrossRef
  • Stability Indicating, pH and pKa Dependent HPLC–DAD Method for the Simultaneous Determination of Weakly Ionizable Empagliflozin, Dapagliflozin and Canagliflozin in Pharmaceutical Formulations
    Shahzad Sharif, Rashida Bashir, Ahmad Adnan, Sabiha Mansoor, Izaz Ahmad, Ayoub Rashid Ch, Muhammad Saqlain Tahir
    Chromatographia.2020; 83(12): 1453.     CrossRef
  • Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials
    José Silva‐Cardoso, Omar Sheikh, Mouhamed Nashawi, Son Pham, Kelly M. Gallegos, Laith R. Dinkha, Robert J. Chilton
    Journal of Diabetes.2020; 12(4): 279.     CrossRef
  • Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes
    Jin Bong Choi, Je Mo Yoo, Ye-Jee Lee, Jae Woong Kim, Seung-Ju Lee, Hee Youn Kim, Dong Sup Lee, Seung-Hyun Ko, Hyun-Sop Choe
    International Neurourology Journal.2020; 24(1): 21.     CrossRef
  • Sodium‐glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter‐organ crosstalk
    Jin Hee Kim, Minyoung Lee, Soo Hyun Kim, So Ra Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Jin Won Cho, Yong‐ho Lee
    Diabetes, Obesity and Metabolism.2019; 21(4): 801.     CrossRef
  • Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
    Scientific Reports.2019;[Epub]     CrossRef
  • SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
    Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li, Xiaochen Yu, Bei Sun, Liming Chen
    Cardiovascular Diabetology.2019;[Epub]     CrossRef
  • An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials
    Ernest Adeghate, Sahar Mohsin, Faisal Adi, Fares Ahmed, Ali Yahya, Huba Kalász, Kornelia Tekes, Ernest A. Adeghate
    Expert Opinion on Investigational Drugs.2019; 28(9): 811.     CrossRef
  • Stability‐indicating chromatographic and chemometric methods for environmentally benign determination of canagliflozin and its major degradation product; A comparative study and greenness assessment
    Aml A. Emam, Nada S. Abdelwahab
    Biomedical Chromatography.2019;[Epub]     CrossRef
  • A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor
    You-Cheol Hwang, Jae Hyeon Kim, Byung-Wan Lee, Woo Je Lee
    Diabetes & Metabolism Journal.2019; 43(6): 898.     CrossRef
  • Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors
    Ji-Yeon Lee, Yongin Cho, Minyoung Lee, You Jin Kim, Yong-ho Lee, Byung-Wan Lee, Bong-Soo Cha, Eun Seok Kang
    Diabetes & Metabolism Journal.2019; 43(2): 158.     CrossRef
  • Comparative Efficacy and Safety Among Sodium-glucose Cotransporter-2 Inhibitors in Type 2 Diabetes – Results from a Retrospective Single-centre Study
    Manash P Baruah, Sanjay Kalra
    European Endocrinology.2019; 15(2): 113.     CrossRef
  • Canagliflozin stability study and ecofriendly chromatographic determination of its degradation product: A comparative study
    Aml A. Emam
    Journal of Separation Science.2018; 41(4): 822.     CrossRef
  • Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial
    Nam Hoon Kim, Soo Lim, Soo Heon Kwak, Min Kyong Moon, Jun Sung Moon, Yong-ho Lee, Ho Chan Cho, Juneyoung Lee, Sin Gon Kim
    BMJ Open.2018; 8(9): e022448.     CrossRef
  • Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting
    YL Shao, KH Yee, SK, Koh, YF Wong, LY Yeoh, S Low, CF Sum
    Singapore Medical Journal.2018; 59(5): 251.     CrossRef
  • Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors
    Soo Lim, Robert H. Eckel, Kwang Kon Koh
    Atherosclerosis.2018; 272: 33.     CrossRef
  • Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats
    Kyung Ae Lee, Heung Yong Jin, Na Young Lee, Yu Ji Kim, Tae Sun Park
    Diabetes & Metabolism Journal.2018; 42(4): 338.     CrossRef
  • The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes
    Yanli Shao, Gwyneth Joy Lim, Chin Lian Chua, Yip Fong Wong, Ester Chai Kheng Yeoh, Serena Kiat Mun Low, Chee Fang Sum
    Diabetes Research and Clinical Practice.2018; 142: 85.     CrossRef
  • Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease
    Dug-Hyun Choi, Chan-Hee Jung, Ji-Oh Mok, Chul-Hee Kim, Sung-Koo Kang, Bo-Yeon Kim
    Endocrinology and Metabolism.2018; 33(3): 387.     CrossRef
  • Comparison between sodium–glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta‐analysis
    Yun Kyung Cho, Ye‐Jee Kim, Yu Mi Kang, Seung Eun Lee, Joong‐Yeol Park, Woo Je Lee, Chang Hee Jung
    Journal of Diabetes Investigation.2018; 9(4): 882.     CrossRef
  • Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
    Eugene Han, Ari Kim, Sung Jae Lee, Je-Yon Kim, Jae Hyeon Kim, Woo Je Lee, Byung-Wan Lee
    Diabetes Therapy.2018; 9(4): 1689.     CrossRef
  • Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
    Eugene Han, Eugene Shin, Gyuri Kim, Ji-Yeon Lee, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
    Frontiers in Endocrinology.2018;[Epub]     CrossRef
  • Clinical parameters affecting dapagliflozin response in patients with type 2 diabetes
    J.-Y. Lee, G. Kim, S.R. Kim, Y.-H. Lee, B.-W. Lee, B.-S. Cha, E.S. Kang
    Diabetes & Metabolism.2017; 43(2): 191.     CrossRef
  • Glucagon and glucagon-like peptide-1 as novel anti-inflammatory and immunomodulatory compounds
    Daniella B.R. Insuela, Vinicius F. Carvalho
    European Journal of Pharmacology.2017; 812: 64.     CrossRef
  • Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J‐STEP/INS): Results of a 16‐week randomized, double‐blind, placebo‐controlled multicentre trial
    Yasuo Terauchi, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku
    Diabetes, Obesity and Metabolism.2017; 19(10): 1397.     CrossRef
  • A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
    Seon-Ah Cha, Yong-Moon Park, Jae-Seung Yun, Tae-Seok Lim, Ki-Ho Song, Ki-Dong Yoo, Yu-Bae Ahn, Seung-Hyun Ko
    Lipids in Health and Disease.2017;[Epub]     CrossRef
  • Morning Spot Urine Glucose-to-Creatinine Ratios Predict Overnight Urinary Glucose Excretion in Patients With Type 2 Diabetes
    So Ra Kim, Yong-ho Lee, Sang-Guk Lee, Sun Hee Lee, Eun Seok Kang, Bong-Soo Cha, Hyun Chul Lee, Jeong-Ho Kim, Byung-Wan Lee
    Annals of Laboratory Medicine.2017; 37(1): 9.     CrossRef
  • The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study
    So Ra Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
    Diabetes Therapy.2017; 8(3): 601.     CrossRef
  • Clinical and Genetic Features of Patients With Type 2 Diabetes and Renal Glycosuria
    Siqian Gong, Jiandong Guo, Xueyao Han, Meng Li, Lingli Zhou, Xiaoling Cai, Yu Zhu, Yingying Luo, Simin Zhang, Xianghai Zhou, Yumin Ma, Linong Ji
    The Journal of Clinical Endocrinology & Metabolism.2017; 102(5): 1548.     CrossRef
  • Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes
    Seok Joon Shin, Sungjin Chung, Soo Jung Kim, Eun-Mi Lee, Young-Hye Yoo, Ji-Won Kim, Yu-Bae Ahn, Eun-Sook Kim, Sung-Dae Moon, Myung-Jun Kim, Seung-Hyun Ko, Kwang-Hyun Baek
    PLOS ONE.2016; 11(11): e0165703.     CrossRef
  • Sodium–glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes
    Stanley S. Schwartz, Intekhab Ahmed
    Current Medical Research and Opinion.2016; 32(5): 907.     CrossRef
  • Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes
    Fida Bacha, Sara Klinepeter Bartz
    Pediatric Diabetes.2016; 17(8): 545.     CrossRef
  • Renal threshold for glucose reabsorption predicts diabetes improvement by sodium‐glucose cotransporter 2 inhibitor therapy
    Aya Osaki, Shuichi Okada, Tsugumichi Saito, Eijiro Yamada, Kumeo Ono, Yawara Niijima, Hiroto Hoshi, Masanobu Yamada
    Journal of Diabetes Investigation.2016; 7(5): 751.     CrossRef
  • Sodium-glucose co-transporter inhibition in the treatment of diabetes: Sweetening the pot
    Carlos A Alvarez, Ian J Neeland, Darren K McGuire
    Diabetes and Vascular Disease Research.2015; 12(2): 74.     CrossRef
  • A simple and sensitive high performance liquid chromatography assay with a fluorescence detector for determination of canagliflozin in human plasma
    Muzaffar Iqbal, Nasr Y. Khalil, Amer M. Alanazi, Khalid A. Al-Rashood
    Analytical Methods.2015; 7(7): 3028.     CrossRef
  • Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years
    Xiang-Yang Liu, Ning Zhang, Rui Chen, Jia-Guo Zhao, Pei Yu
    Journal of Diabetes and its Complications.2015; 29(8): 1295.     CrossRef
  • Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin
    Arshpreet Kaur, Stephen J Winters
    Endocrinology, Diabetes & Metabolism Case Reports.2015;[Epub]     CrossRef
  • Pharmacological treatment and therapeutic perspectives of metabolic syndrome
    Soo Lim, Robert H. Eckel
    Reviews in Endocrine and Metabolic Disorders.2014; 15(4): 329.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer